カテゴリ： 世界, 医療/バイオ, Market Monitor Global

脊髄性筋萎縮症治療のグローバル市場展望 2023年-2029年：LMI-070、ND-602、NT-1654、ヌシネルセン、NXD-30001、その他

■ 英語タイトル：Spinal Muscular Atrophy Medicine Market, Global Outlook and Forecast 2023-2029

調査会社Market Monitor Global社が発行したリサーチレポート（データ管理コード：MMG23LY8679）■ 発行会社/調査会社：Market Monitor Global
■ 商品コード：MMG23LY8679
■ 発行日：2023年7月
■ 調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
■ 産業分野：医薬品＆ヘルスケア
■ ページ数：116
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Market Monitor Global社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[脊髄性筋萎縮症治療のグローバル市場展望 2023年-2029年：LMI-070、ND-602、NT-1654、ヌシネルセン、NXD-30001、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査レポートは次の情報を含め、世界の脊髄性筋萎縮症治療市場規模と予測を収録しています。・世界の脊髄性筋萎縮症治療市場：売上、2018年-2023年、2024年-2029年
・世界の脊髄性筋萎縮症治療市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の脊髄性筋萎縮症治療市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「LMI-070」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

脊髄性筋萎縮症治療のグローバル主要企業は、Astellas Pharma Inc.、 AveXis, Inc.、 Bioblast Pharma Ltd.、 Cytokinetics, Inc. 24、 F. Hoffmann-La Roche Ltd.、 Genethon、 Genzyme Corporation、 GMP-Orphan SAS、 Ionis Pharmaceuticals, Inc.、 Longevity Biotech, Inc、 Neurodyn Inc.、 Neurotune AG、 Novartis AG、 Sarepta Therapeutics, Inc.、 Voyager Therapeutics, Inc.、 Vybion, Inc.、 WAVE Life Sciences Ltd.などです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、脊髄性筋萎縮症治療のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の脊髄性筋萎縮症治療市場：タイプ別、2018年-2023年、2024年-2029年
世界の脊髄性筋萎縮症治療市場：タイプ別市場シェア、2022年
・LMI-070、ND-602、NT-1654、ヌシネルセン、NXD-30001、その他

世界の脊髄性筋萎縮症治療市場：用途別、2018年-2023年、2024年-2029年
世界の脊髄性筋萎縮症治療市場：用途別市場シェア、2022年
・病院、クリニック、その他

世界の脊髄性筋萎縮症治療市場：地域・国別、2018年-2023年、2024年-2029年
世界の脊髄性筋萎縮症治療市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における脊髄性筋萎縮症治療のグローバル売上、2018年-2023年
・主要企業における脊髄性筋萎縮症治療のグローバル売上シェア、2022年
・主要企業における脊髄性筋萎縮症治療のグローバル販売量、2018年-2023年
・主要企業における脊髄性筋萎縮症治療のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Astellas Pharma Inc.、 AveXis, Inc.、 Bioblast Pharma Ltd.、 Cytokinetics, Inc. 24、 F. Hoffmann-La Roche Ltd.、 Genethon、 Genzyme Corporation、 GMP-Orphan SAS、 Ionis Pharmaceuticals, Inc.、 Longevity Biotech, Inc、 Neurodyn Inc.、 Neurotune AG、 Novartis AG、 Sarepta Therapeutics, Inc.、 Voyager Therapeutics, Inc.、 Vybion, Inc.、 WAVE Life Sciences Ltd.

*************************************************************

・調査・分析レポートの概要
脊髄性筋萎縮症治療市場の定義
市場セグメント
世界の脊髄性筋萎縮症治療市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の脊髄性筋萎縮症治療市場規模
世界の脊髄性筋萎縮症治療市場規模：2022年 VS 2029年
世界の脊髄性筋萎縮症治療市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの脊髄性筋萎縮症治療の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の脊髄性筋萎縮症治療製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：LMI-070、ND-602、NT-1654、ヌシネルセン、NXD-30001、その他
脊髄性筋萎縮症治療のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院、クリニック、その他
脊髄性筋萎縮症治療の用途別グローバル売上・予測

・地域別市場分析
地域別脊髄性筋萎縮症治療市場規模 2022年と2029年
地域別脊髄性筋萎縮症治療売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Astellas Pharma Inc.、 AveXis, Inc.、 Bioblast Pharma Ltd.、 Cytokinetics, Inc. 24、 F. Hoffmann-La Roche Ltd.、 Genethon、 Genzyme Corporation、 GMP-Orphan SAS、 Ionis Pharmaceuticals, Inc.、 Longevity Biotech, Inc、 Neurodyn Inc.、 Neurotune AG、 Novartis AG、 Sarepta Therapeutics, Inc.、 Voyager Therapeutics, Inc.、 Vybion, Inc.、 WAVE Life Sciences Ltd.
...

This report aims to provide a comprehensive presentation of the global market for Spinal Muscular Atrophy Medicine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Spinal Muscular Atrophy Medicine. This report contains market size and forecasts of Spinal Muscular Atrophy Medicine in global, including the following market information:
Global Spinal Muscular Atrophy Medicine Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Spinal Muscular Atrophy Medicine Market Sales, 2018-2023, 2024-2029, (K Pcs)
Global top five Spinal Muscular Atrophy Medicine companies in 2022 (%)
The global Spinal Muscular Atrophy Medicine market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
LMI-070 Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Spinal Muscular Atrophy Medicine include Astellas Pharma Inc., AveXis, Inc., Bioblast Pharma Ltd., Cytokinetics, Inc. 24, F. Hoffmann-La Roche Ltd., Genethon, Genzyme Corporation, GMP-Orphan SAS and Ionis Pharmaceuticals, Inc., etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Spinal Muscular Atrophy Medicine manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Spinal Muscular Atrophy Medicine Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global Spinal Muscular Atrophy Medicine Market Segment Percentages, by Type, 2022 (%)
LMI-070
ND-602
NT-1654
Nusinersen
NXD-30001
Others
Global Spinal Muscular Atrophy Medicine Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global Spinal Muscular Atrophy Medicine Market Segment Percentages, by Application, 2022 (%)
Hospital
Clinic
Others
Global Spinal Muscular Atrophy Medicine Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global Spinal Muscular Atrophy Medicine Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Spinal Muscular Atrophy Medicine revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Spinal Muscular Atrophy Medicine revenues share in global market, 2022 (%)
Key companies Spinal Muscular Atrophy Medicine sales in global market, 2018-2023 (Estimated), (K Pcs)
Key companies Spinal Muscular Atrophy Medicine sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Astellas Pharma Inc.
AveXis, Inc.
Bioblast Pharma Ltd.
Cytokinetics, Inc. 24
F. Hoffmann-La Roche Ltd.
Genethon
Genzyme Corporation
GMP-Orphan SAS
Ionis Pharmaceuticals, Inc.
Longevity Biotech, Inc
Neurodyn Inc.
Neurotune AG
Novartis AG
Sarepta Therapeutics, Inc.
Voyager Therapeutics, Inc.
Vybion, Inc.
WAVE Life Sciences Ltd.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Spinal Muscular Atrophy Medicine, market overview.
Chapter 2: Global Spinal Muscular Atrophy Medicine market size in revenue and volume.
Chapter 3: Detailed analysis of Spinal Muscular Atrophy Medicine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Spinal Muscular Atrophy Medicine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Spinal Muscular Atrophy Medicine capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Introduction to Research & Analysis Reports
1.1 Spinal Muscular Atrophy Medicine Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Spinal Muscular Atrophy Medicine Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Spinal Muscular Atrophy Medicine Overall Market Size
2.1 Global Spinal Muscular Atrophy Medicine Market Size: 2022 VS 2029
2.2 Global Spinal Muscular Atrophy Medicine Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Spinal Muscular Atrophy Medicine Sales: 2018-2029
3 Company Landscape
3.1 Top Spinal Muscular Atrophy Medicine Players in Global Market
3.2 Top Global Spinal Muscular Atrophy Medicine Companies Ranked by Revenue
3.3 Global Spinal Muscular Atrophy Medicine Revenue by Companies
3.4 Global Spinal Muscular Atrophy Medicine Sales by Companies
3.5 Global Spinal Muscular Atrophy Medicine Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Spinal Muscular Atrophy Medicine Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Spinal Muscular Atrophy Medicine Product Type
3.8 Tier 1, Tier 2 and Tier 3 Spinal Muscular Atrophy Medicine Players in Global Market
3.8.1 List of Global Tier 1 Spinal Muscular Atrophy Medicine Companies
3.8.2 List of Global Tier 2 and Tier 3 Spinal Muscular Atrophy Medicine Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Spinal Muscular Atrophy Medicine Market Size Markets, 2022 & 2029
4.1.2 LMI-070
4.1.3 ND-602
4.1.4 NT-1654
4.1.5 Nusinersen
4.1.6 NXD-30001
4.1.7 Others
4.2 By Type – Global Spinal Muscular Atrophy Medicine Revenue & Forecasts
4.2.1 By Type – Global Spinal Muscular Atrophy Medicine Revenue, 2018-2023
4.2.2 By Type – Global Spinal Muscular Atrophy Medicine Revenue, 2024-2029
4.2.3 By Type – Global Spinal Muscular Atrophy Medicine Revenue Market Share, 2018-2029
4.3 By Type – Global Spinal Muscular Atrophy Medicine Sales & Forecasts
4.3.1 By Type – Global Spinal Muscular Atrophy Medicine Sales, 2018-2023
4.3.2 By Type – Global Spinal Muscular Atrophy Medicine Sales, 2024-2029
4.3.3 By Type – Global Spinal Muscular Atrophy Medicine Sales Market Share, 2018-2029
4.4 By Type – Global Spinal Muscular Atrophy Medicine Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Spinal Muscular Atrophy Medicine Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Others
5.2 By Application – Global Spinal Muscular Atrophy Medicine Revenue & Forecasts
5.2.1 By Application – Global Spinal Muscular Atrophy Medicine Revenue, 2018-2023
5.2.2 By Application – Global Spinal Muscular Atrophy Medicine Revenue, 2024-2029
5.2.3 By Application – Global Spinal Muscular Atrophy Medicine Revenue Market Share, 2018-2029
5.3 By Application – Global Spinal Muscular Atrophy Medicine Sales & Forecasts
5.3.1 By Application – Global Spinal Muscular Atrophy Medicine Sales, 2018-2023
5.3.2 By Application – Global Spinal Muscular Atrophy Medicine Sales, 2024-2029
5.3.3 By Application – Global Spinal Muscular Atrophy Medicine Sales Market Share, 2018-2029
5.4 By Application – Global Spinal Muscular Atrophy Medicine Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Spinal Muscular Atrophy Medicine Market Size, 2022 & 2029
6.2 By Region – Global Spinal Muscular Atrophy Medicine Revenue & Forecasts
6.2.1 By Region – Global Spinal Muscular Atrophy Medicine Revenue, 2018-2023
6.2.2 By Region – Global Spinal Muscular Atrophy Medicine Revenue, 2024-2029
6.2.3 By Region – Global Spinal Muscular Atrophy Medicine Revenue Market Share, 2018-2029
6.3 By Region – Global Spinal Muscular Atrophy Medicine Sales & Forecasts
6.3.1 By Region – Global Spinal Muscular Atrophy Medicine Sales, 2018-2023
6.3.2 By Region – Global Spinal Muscular Atrophy Medicine Sales, 2024-2029
6.3.3 By Region – Global Spinal Muscular Atrophy Medicine Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Spinal Muscular Atrophy Medicine Revenue, 2018-2029
6.4.2 By Country – North America Spinal Muscular Atrophy Medicine Sales, 2018-2029
6.4.3 US Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.4.4 Canada Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.4.5 Mexico Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Spinal Muscular Atrophy Medicine Revenue, 2018-2029
6.5.2 By Country – Europe Spinal Muscular Atrophy Medicine Sales, 2018-2029
6.5.3 Germany Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.5.4 France Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.5.5 U.K. Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.5.6 Italy Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.5.7 Russia Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.5.8 Nordic Countries Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.5.9 Benelux Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Spinal Muscular Atrophy Medicine Revenue, 2018-2029
6.6.2 By Region – Asia Spinal Muscular Atrophy Medicine Sales, 2018-2029
6.6.3 China Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.6.4 Japan Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.6.5 South Korea Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.6.6 Southeast Asia Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.6.7 India Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Spinal Muscular Atrophy Medicine Revenue, 2018-2029
6.7.2 By Country – South America Spinal Muscular Atrophy Medicine Sales, 2018-2029
6.7.3 Brazil Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.7.4 Argentina Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Spinal Muscular Atrophy Medicine Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Spinal Muscular Atrophy Medicine Sales, 2018-2029
6.8.3 Turkey Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.8.4 Israel Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.8.5 Saudi Arabia Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.8.6 UAE Spinal Muscular Atrophy Medicine Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Astellas Pharma Inc.
7.1.1 Astellas Pharma Inc. Company Summary
7.1.2 Astellas Pharma Inc. Business Overview
7.1.3 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Major Product Offerings
7.1.4 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales and Revenue in Global (2018-2023)
7.1.5 Astellas Pharma Inc. Key News & Latest Developments
7.2 AveXis, Inc.
7.2.1 AveXis, Inc. Company Summary
7.2.2 AveXis, Inc. Business Overview
7.2.3 AveXis, Inc. Spinal Muscular Atrophy Medicine Major Product Offerings
7.2.4 AveXis, Inc. Spinal Muscular Atrophy Medicine Sales and Revenue in Global (2018-2023)
7.2.5 AveXis, Inc. Key News & Latest Developments
7.3 Bioblast Pharma Ltd.
7.3.1 Bioblast Pharma Ltd. Company Summary
7.3.2 Bioblast Pharma Ltd. Business Overview
7.3.3 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Major Product Offerings
7.3.4 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales and Revenue in Global (2018-2023)
7.3.5 Bioblast Pharma Ltd. Key News & Latest Developments
7.4 Cytokinetics, Inc. 24
7.4.1 Cytokinetics, Inc. 24 Company Summary
7.4.2 Cytokinetics, Inc. 24 Business Overview
7.4.3 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Major Product Offerings
7.4.4 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales and Revenue in Global (2018-2023)
7.4.5 Cytokinetics, Inc. 24 Key News & Latest Developments
7.5 F. Hoffmann-La Roche Ltd.
7.5.1 F. Hoffmann-La Roche Ltd. Company Summary
7.5.2 F. Hoffmann-La Roche Ltd. Business Overview
7.5.3 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Major Product Offerings
7.5.4 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales and Revenue in Global (2018-2023)
7.5.5 F. Hoffmann-La Roche Ltd. Key News & Latest Developments
7.6 Genethon
7.6.1 Genethon Company Summary
7.6.2 Genethon Business Overview
7.6.3 Genethon Spinal Muscular Atrophy Medicine Major Product Offerings
7.6.4 Genethon Spinal Muscular Atrophy Medicine Sales and Revenue in Global (2018-2023)
7.6.5 Genethon Key News & Latest Developments
7.7 Genzyme Corporation
7.7.1 Genzyme Corporation Company Summary
7.7.2 Genzyme Corporation Business Overview
7.7.3 Genzyme Corporation Spinal Muscular Atrophy Medicine Major Product Offerings
7.7.4 Genzyme Corporation Spinal Muscular Atrophy Medicine Sales and Revenue in Global (2018-2023)
7.7.5 Genzyme Corporation Key News & Latest Developments
7.8 GMP-Orphan SAS
7.8.1 GMP-Orphan SAS Company Summary
7.8.2 GMP-Orphan SAS Business Overview
7.8.3 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Major Product Offerings
7.8.4 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales and Revenue in Global (2018-2023)
7.8.5 GMP-Orphan SAS Key News & Latest Developments
7.9 Ionis Pharmaceuticals, Inc.
7.9.1 Ionis Pharmaceuticals, Inc. Company Summary
7.9.2 Ionis Pharmaceuticals, Inc. Business Overview
7.9.3 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Major Product Offerings
7.9.4 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales and Revenue in Global (2018-2023)
7.9.5 Ionis Pharmaceuticals, Inc. Key News & Latest Developments
7.10 Longevity Biotech, Inc
7.10.1 Longevity Biotech, Inc Company Summary
7.10.2 Longevity Biotech, Inc Business Overview
7.10.3 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Major Product Offerings
7.10.4 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales and Revenue in Global (2018-2023)
7.10.5 Longevity Biotech, Inc Key News & Latest Developments
7.11 Neurodyn Inc.
7.11.1 Neurodyn Inc. Company Summary
7.11.2 Neurodyn Inc. Spinal Muscular Atrophy Medicine Business Overview
7.11.3 Neurodyn Inc. Spinal Muscular Atrophy Medicine Major Product Offerings
7.11.4 Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales and Revenue in Global (2018-2023)
7.11.5 Neurodyn Inc. Key News & Latest Developments
7.12 Neurotune AG
7.12.1 Neurotune AG Company Summary
7.12.2 Neurotune AG Spinal Muscular Atrophy Medicine Business Overview
7.12.3 Neurotune AG Spinal Muscular Atrophy Medicine Major Product Offerings
7.12.4 Neurotune AG Spinal Muscular Atrophy Medicine Sales and Revenue in Global (2018-2023)
7.12.5 Neurotune AG Key News & Latest Developments
7.13 Novartis AG
7.13.1 Novartis AG Company Summary
7.13.2 Novartis AG Spinal Muscular Atrophy Medicine Business Overview
7.13.3 Novartis AG Spinal Muscular Atrophy Medicine Major Product Offerings
7.13.4 Novartis AG Spinal Muscular Atrophy Medicine Sales and Revenue in Global (2018-2023)
7.13.5 Novartis AG Key News & Latest Developments
7.14 Sarepta Therapeutics, Inc.
7.14.1 Sarepta Therapeutics, Inc. Company Summary
7.14.2 Sarepta Therapeutics, Inc. Business Overview
7.14.3 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Major Product Offerings
7.14.4 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales and Revenue in Global (2018-2023)
7.14.5 Sarepta Therapeutics, Inc. Key News & Latest Developments
7.15 Voyager Therapeutics, Inc.
7.15.1 Voyager Therapeutics, Inc. Company Summary
7.15.2 Voyager Therapeutics, Inc. Business Overview
7.15.3 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Major Product Offerings
7.15.4 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales and Revenue in Global (2018-2023)
7.15.5 Voyager Therapeutics, Inc. Key News & Latest Developments
7.16 Vybion, Inc.
7.16.1 Vybion, Inc. Company Summary
7.16.2 Vybion, Inc. Business Overview
7.16.3 Vybion, Inc. Spinal Muscular Atrophy Medicine Major Product Offerings
7.16.4 Vybion, Inc. Spinal Muscular Atrophy Medicine Sales and Revenue in Global (2018-2023)
7.16.5 Vybion, Inc. Key News & Latest Developments
7.17 WAVE Life Sciences Ltd.
7.17.1 WAVE Life Sciences Ltd. Company Summary
7.17.2 WAVE Life Sciences Ltd. Business Overview
7.17.3 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Major Product Offerings
7.17.4 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales and Revenue in Global (2018-2023)
7.17.5 WAVE Life Sciences Ltd. Key News & Latest Developments
8 Global Spinal Muscular Atrophy Medicine Production Capacity, Analysis
8.1 Global Spinal Muscular Atrophy Medicine Production Capacity, 2018-2029
8.2 Spinal Muscular Atrophy Medicine Production Capacity of Key Manufacturers in Global Market
8.3 Global Spinal Muscular Atrophy Medicine Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Spinal Muscular Atrophy Medicine Supply Chain Analysis
10.1 Spinal Muscular Atrophy Medicine Industry Value Chain
10.2 Spinal Muscular Atrophy Medicine Upstream Market
10.3 Spinal Muscular Atrophy Medicine Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Spinal Muscular Atrophy Medicine Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 脊椎矯正装置のグローバル市場展望 2023年-2029年：フレキシブルタイプ、リジッドタイプ
  • 椎体間固定術のグローバル市場展望 2023年-2029年：頸椎固定装置、椎体間固定装置、胸腰椎装置
  • 脳脊髄液（CSF）シャント装置のグローバル市場展望 2023年-2029年：固定バルブ、可変バルブ
  • 脊髄インプラント消耗品のグローバル市場展望 2023年-2029年：椎弓根スクリュー、コネクティングロッド、コネクティング鋼板、固定具、支持具
  • 処方頭痛薬のグローバル市場展望 2023年-2029年：スマトリプタン、リザトリプタン、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(MMG23LY8679 )"脊髄性筋萎縮症治療のグローバル市場展望 2023年-2029年：LMI-070、ND-602、NT-1654、ヌシネルセン、NXD-30001、その他" (英文：Spinal Muscular Atrophy Medicine Market, Global Outlook and Forecast 2023-2029)はMarket Monitor Global社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。